We will conduct a phase IV double-blind, randomised, placebo-controlled clinical trial to optimise the effectiveness of RV1 oral rotavirus vaccine among Indigenous infants. Northern Territory Indigenous infants will be given either a third dose of rotavirus vaccine (Rotarix – RV1) or a matched placebo between the ages of 6 to 12 months. We will compare the immune responses between the two groups (as a marker of immune protection against rotavirus) as well as the frequency of hospital and clinic presentation for gastroenteritis in the first three years of life.

https://hdl.handle.net/10137/12781

Viral Gastroenteritis Due to Rotavirus

A phase IV, double blind, randomised, placebo controlled clinical trial of a third scheduled dose of RV1 rotavirus vaccine in Australian Indigenous infants to improve protection against gastroenteritis

Interventional/Clinical trials research

Project